ANTX Nasdaq· AN2 Therapeutics Inc
FundamentalsNews digest Peer analysis
ANTX Nasdaq· AN2 Therapeutics Inc
Earnings report Q3 2023

ANTX Reports Strong Revenue Growth in Latest Quarter

Segments of Revenue

AN2 Therapeutics, Inc. (ANTX) reported robust revenue growth in the latest quarter. The company generated revenue from two segments: research and development (R&D) and general and administrative (G&A).

In the R&D segment, ANTX recorded revenue of $14.43 million, representing a significant increase from $7.43 million in the same quarter last year. This growth can be attributed to the progress made in the development of their initial product candidate, epetraborole, which is undergoing a pivotal Phase 2/3 clinical trial for the treatment of non-tuberculous mycobacterial (NTM) lung disease.

The G&A segment generated revenue of $3.75 million, slightly higher than the $3.34 million reported in the previous year's quarter. This increase can be attributed to effective cost management and operational efficiencies.


ANTX demonstrated strong financial performance in the latest quarter, primarily driven by the significant increase in revenue from the R&D segment. The progress made in the development of epetraborole, particularly in the pivotal clinical trial, has contributed to the company's revenue growth. This indicates the potential of their product candidate to address the high unmet needs in the treatment of rare, chronic, and serious infectious diseases.

Management has emphasized their commitment to advancing the development of epetraborole and leveraging its potential to provide a once-daily, oral treatment for patients with NTM lung disease. The company's focus on addressing treatment-refractory Mycobacterium avium complex (MAC) lung disease highlights their dedication to tackling challenging infectious diseases.


While ANTX reported strong revenue growth, it is important to note that the company is still in the clinical-stage of development. As a result, they continue to incur significant research and development expenses, which amounted to $14.43 million in the latest quarter. These expenses may impact the company's profitability in the short term.

Additionally, ANTX operates in a highly competitive biopharmaceutical industry, where success is dependent on the successful development and commercialization of innovative treatments. The company will need to navigate regulatory challenges, clinical trial outcomes, and potential market competition to achieve long-term success.


In the latest quarter, ANTX reported a net loss of $16.71 million, compared to a net loss of $11.34 million in the same quarter last year. However, it is worth noting that the net loss was partially offset by other income of $1.47 million, primarily driven by favorable investment returns.


ANTX delivered strong revenue growth in the latest quarter, driven by the progress made in the development of their initial product candidate, epetraborole. The company's focus on addressing rare, chronic, and serious infectious diseases has positioned them well in the market. However, ANTX continues to face challenges associated with being in the clinical-stage of development and operating in a competitive industry. Overall, ANTX's financial performance reflects their commitment to advancing innovative treatments and addressing unmet medical needs.

Source documents

Form 10-Q  filed on Nov 09, 2023
6 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS beat by 3.72%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.